←Back to Expert Scholars
Translational Medicine / 转化医学MET Exon 14 Skipping Alterations
Jia Qing Tong
MD, PhD
🏢Peking University Cancer Hospital🌐China
Associate Professor of Oncology
40
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jia Qing Tong has led pivotal Chinese clinical trials of savolitinib for MET exon 14 skipping NSCLC. His research addresses the unique molecular epidemiology of MET alterations in Chinese patients. He has contributed to regulatory approval of MET-targeted therapy in China.
Share:
🧪Research Fields 研究领域
MET exon 14 skipping
Savolitinib
Chinese patient population
Molecular diagnostics
Targeted therapy Asia
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jia Qing Tong 的研究动态
Follow Jia Qing Tong's research updates
留下邮箱，当我们发布与 Jia Qing Tong（Peking University Cancer Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment